Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) ...